WallStreetZenWallStreetZen

NASDAQ: ASND
Ascendis Pharma A Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ASND

Based on 17 analysts offering 12 month price targets for Ascendis Pharma A

Min Forecast
$269.00+9.73%
Avg Forecast
$313.88+28.04%
Max Forecast
$344.00+40.32%

Should I buy or sell ASND stock?

Based on 17 analysts offering ratings for Ascendis Pharma A.

Strong Buy
Strong Buy
10 analysts 58.82%
Buy
7 analysts 41.18%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model "Buy" agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their ASND stock forecasts and price targets.

ASND stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-10-26
lockedlocked$00.00+00.00%2026-10-15
lockedlocked$00.00+00.00%2026-09-25
lockedlocked$00.00+00.00%2026-09-15
lockedlocked$00.00+00.00%2026-09-02
Morgan Stanley
Top 30%
71
Strong BuyMaintains$273.00+11.36%2026-09-01
Wedbush
Bottom 3%
3
BuyReiterates$327.00+33.39%2026-09-01
Bank of America
Bottom 11%
11
Strong BuyMaintains$304.00+24.01%2026-08-31
Jefferies
Top 18%
83
Strong BuyMaintains$330.00+34.61%2026-08-31
Stifel Nicolaus
Top 15%
86
Strong BuyMaintains$326.00+32.98%2026-08-31

1 of 2

Forecast return on equity

Is ASND forecast to generate an efficient return?

Company
49.04%
Industry
23.42%
Market
178.3%
ASND's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ASND forecast to generate an efficient return on assets?

Company
30.81%
Industry
23.24%
ASND is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ASND earnings per share forecast

What is ASND's earnings per share in the next 3 years based on estimates from 23 analysts?

Avg 1 year Forecast
$15.08+11.72%
Avg 2 year Forecast
$9.65-28.5%
Avg 3 year Forecast
$13.70+1.48%
ASND's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

ASND revenue forecast

What is ASND's revenue in the next 3 years based on estimates from 23 analysts?

Avg 1 year Forecast
$1.4B+17.67%
Avg 2 year Forecast
$2.1B+72.72%
Avg 3 year Forecast
$2.6B+119.53%
ASND's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ASND earnings growth forecast

How is ASND forecast to perform vs Biotechnology companies and vs the US market?

Company
-4.94%
Industry
11.53%
Market
32.91%
ASND's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
ASND's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
ASND's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

ASND revenue growth forecast

How is ASND forecast to perform vs Biotechnology companies and vs the US market?

Company
29.63%
Industry
31.1%
Market
13.3%
ASND's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ASND's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ASND vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ASND$245.15$313.88+28.04%Strong Buy
EXEL$65.11$53.55-17.76%Hold
HALO$128.01$104.14-18.64%Buy
JAZZ$205.70$296.56+44.17%Strong Buy
BBIO$68.15$110.43+62.04%Strong Buy
View Top Biotech Stocks

Ascendis Pharma A Stock Forecast FAQ

Is Ascendis Pharma A Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 17 Wall Street analysts covering (NASDAQ: ASND) stock is to Strong Buy ASND stock.

Out of 17 analysts, 10 (58.82%) are recommending ASND as a Strong Buy, 7 (41.18%) are recommending ASND as a Buy, 0 (0%) are recommending ASND as a Hold, 0 (0%) are recommending ASND as a Sell, and 0 (0%) are recommending ASND as a Strong Sell.

If you're new to stock investing, here's how to buy Ascendis Pharma A stock.

What is ASND's earnings growth forecast for 2026-2028?

(NASDAQ: ASND) Ascendis Pharma A's forecast annual earnings growth rate of -4.94% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.53%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.91%.

Ascendis Pharma A's earnings in 2026 is $855,545,559.On average, 23 Wall Street analysts forecast ASND's earnings for 2026 to be $990,510,739, with the lowest ASND earnings forecast at $808,359,318, and the highest ASND earnings forecast at $1,245,362,484. On average, 23 Wall Street analysts forecast ASND's earnings for 2027 to be $633,944,210, with the lowest ASND earnings forecast at $402,892,463, and the highest ASND earnings forecast at $1,031,871,773.

In 2028, ASND is forecast to generate $899,678,020 in earnings, with the lowest earnings forecast at $449,231,532 and the highest earnings forecast at $1,543,946,070.

What is ASND's revenue growth forecast for 2026-2028?

(NASDAQ: ASND) Ascendis Pharma A's forecast annual revenue growth rate of 29.63% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.1%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.3%.

Ascendis Pharma A's revenue in 2026 is $1,207,635,524.On average, 23 Wall Street analysts forecast ASND's revenue for 2026 to be $91,942,597,600, with the lowest ASND revenue forecast at $85,440,942,484, and the highest ASND revenue forecast at $99,823,391,680. On average, 23 Wall Street analysts forecast ASND's revenue for 2027 to be $134,958,598,620, with the lowest ASND revenue forecast at $121,626,921,968, and the highest ASND revenue forecast at $158,732,327,428.

In 2028, ASND is forecast to generate $171,538,617,808 in revenue, with the lowest revenue forecast at $143,890,165,244 and the highest revenue forecast at $207,396,230,872.

What is ASND's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ASND) forecast ROA is 30.81%, which is higher than the forecast US Biotechnology industry average of 23.24%.

What is ASND's Price Target?

According to 17 Wall Street analysts that have issued a 1 year ASND price target, the average ASND price target is $313.88, with the highest ASND stock price forecast at $344.00 and the lowest ASND stock price forecast at $269.00.

On average, Wall Street analysts predict that Ascendis Pharma A's share price could reach $313.88 by Oct 26, 2027. The average Ascendis Pharma A stock price prediction forecasts a potential upside of 28.04% from the current ASND share price of $245.15.

What is ASND's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ASND) Ascendis Pharma A's current Earnings Per Share (EPS) is $13.70. On average, analysts forecast that ASND's EPS will be $15.08 for 2026, with the lowest EPS forecast at $12.31, and the highest EPS forecast at $18.96. On average, analysts forecast that ASND's EPS will be $9.65 for 2027, with the lowest EPS forecast at $6.13, and the highest EPS forecast at $15.71. In 2028, ASND's EPS is forecast to hit $13.70 (min: $6.84, max: $23.51).

What is ASND's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ASND) forecast ROE is 49.04%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.